Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed non-small cell lung cancer (NSCLC)

- Locally advanced or metastatic disease

- Measurable disease

- Failed at least one prior chemotherapy regimen

- No more than 6 discrete active extracranial lesions (≤ 3 in the liver and ≤ 3 in the
lung) identified by positron emission tomography (PET) and by correlative plain film,
CT scan, or MRI within 8 weeks prior to the initiation of stereotactic body
radiotherapy (SBRT)

- Residual PET activity is not considered a site of active disease if the CT scan
appearance is stable or improved over a period of ≥ 3 months (for patients who
received prior radiotherapy to the primary site in the lung)

- Patients who received prior radiotherapy to the primary site will be ineligible
for the study if there is CT scan evidence of disease progression within the
past 3 months

- Patients with unirradiated primary sites are potentially eligible for the study

- No more than 2 contiguous vertebral metastases will be considered a single site
of disease

- No metastatic disease invading the esophagus, stomach, intestines, or mesenteric
lymph nodes

- No cutaneous metastasis of NSCLC

- No known brain metastases

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- AST and ALT ≤ 2 times upper limit of normal (ULN)

- Total bilirubin ≤ 2 times ULN

- Alkaline phosphatase ≤ 5 times ULN

- Granulocyte count ≥ 1,500/mm³

- Serum creatinine ≤ 1.5 times ULN

- FEV1 ≥ 1 L (for patients who will be receiving SBRT for lung tumors and who are known
or suspected by the treating radiation oncologist to have compromised lung function)

- Not pregnant

- Negative pregnancy test

- Fertile patients must use effective contraception

- No serious, uncontrolled infection(s)

- No significant weight loss (> 10%) within the past 3 months

- No other carcinoma within the past 5 years except cured nonmelanoma skin cancer or
treated in situ cervical cancer

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 4 weeks since prior participation in an investigational drug study

- No prior EGFR inhibitors